Burkitt Lymphoma - 25 Studies Found
Completed |
: Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma :
: 2011-02-02 : Drug: Chemotherapy-Rituximab combination Short cycles of high-dose and conventional chemotherapy in comb |
Terminated |
: Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma :
|
Completed |
: Rituximab Combined With Chemotherapy in Burkitt`s Lymphoma :
: 2006-10-13 : Drug: RITUXIMAB 375 mg/m2/d day 1 |
Completed |
: Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma :
: 2012-01-06 :
|
Completed |
: LMBA02 Protocol for Patients With a Burkitt Lymphoma : Burkitt Lymphoma : 2005-09-12 : Drug: rituximab |
Terminated |
: Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL : Burkitt Lymphoma : 2005-09-12 : Drug: Rituximab |
Active, not recruiting |
: Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma :
|
Completed |
: Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia : B-cell Acute Lymphoblastic Leukemia : 2006-02-08 : Drug: forodesine hydrochloride (BCX-1777) |
Recruiting |
: The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL). : B-cell Acute Lymphoblastic Leukemia : 2016-09-29 :
|
Active, not recruiting |
: T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia : Relapsed B-Cell Acute Lymphoblastic Leukemia : 2013-05-21 :
|